A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Sponsor
Boehringer Ingelheim
Study ID
NCT04098575
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals

Key Dates

Start date
Sep 16, 2019
Status verified
Mar 2021
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
9,571 participants (actual)

Arms

  • Arm: Patients receiving Empagliflozin until mid Sep 2015
    Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
  • Arm: Patients receiving Empagliflozin until CV Label Change time
    Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
  • Arm: Patients receiving Empagliflozin until last available data cut
    Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3

Primary Outcome Measure

Percentage of Participants With Previous Occurence of Cardiovascular Comorbidities [ Time Frame: At baseline. ]

Related Studies